Press release
Mar 6, 2015

U.S. FDA filing acceptance of NDAs for QVA149 and NVA237

Tokyo, Japan – 6 March 2015: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) confirms that Novartis New Drug Applications (NDAs) for QVA149 and NVA237 for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) have been accepted for review by the US Food and Drug Administration (FDA). The filings were submitted by Novartis in Q4 2014. The acceptances trigger milestone payments to Sosei of $12.5m and $7.5m respectively.